One Two
Sie sind hier: Startseite Publikationen

Publikationen

2020

Bermudez M, Grabowski M, Murgueitio MS, Tiemann N, Varga P, Rudolf T, Wolber G, Weindl G, Rademann J (2020) Biological characterization, mechanistic investigation and structure-activity relationships of chemically stable TLR2 antagonists. ChemMedChem. doi: 10.1002/cmdc.202000060

Grabowski M, Bermudez M, Rudolf T, Šribar D, Varga P, Murgueitio MS, Wolber G, Rademann J, Weindl G (2020) Identification and validation of a novel dual small-molecule TLR2/8 antagonist. Biochem Pharmacol 113957. doi: 10.1016/j.bcp.2020.113957 

Lübow C, Bockstiegel J, Weindl G (2020) Lysosomotropic drugs enhance pro-inflammatory responses to IL-1β in macrophages by inhibiting internalization of the IL-1 receptor. Biochem Pharmacol 175:113864. doi: 10.1016/j.bcp.2020.113864

Grabowski M, Murgueitio MS, Bermudez M, Wolber G, Weindl G (2020) The novel small-molecule antagonist MMG-11 preferentially inhibits TLR2/1 signaling. Biochem Pharmacol 171:113687. doi: 10.1016/j.bcp.2019.113687

 

2019

Müller G, Lübow C, Weindl G (2019) Lysosomotropic beta blockers induce oxidative stress and IL23A production in Langerhans cells. Autophagy. doi: 10.1080/15548627.2019.1686728

Šribar D, Grabowski M, Murgueitio MS, Bermudez M, Weindl G, Wolber G (2019) Identification and characterization of a novel chemotype for human TLR8 inhibitors. Eur J Med Chem 179:744-752. doi: 10.1016/j.ejmech.2019.06.084

Brandenburg K, Heinbockel L, Weindl G, Wiesmüller KH, Schürholz T, Correa W, Gutsmann T, Mauss K, Martinez-de-Tejada G, Garidel P (2019) Development of Antimicrobial Peptides Based on Limulus Anti-Lipopolysaccharide Factor (LALF). In: Williams K. (eds) Endotoxin Detection and Control in Pharma, Limulus, and Mammalian Systems. Springer, Cham. p. 683-706. doi: 10.1007/978-3-030-17148-3_19

Schramm S, Agnetta L, Bermudez M, Gerwe H, Irmen M, Holze J, Littmann T, Wolber G, Tränkle C, Decker M (2019) Novel BQCA- and TBPB-Derived M1 Receptor Hybrid Ligands: Orthosteric Carbachol Differentially Regulates Partial Agonism. ChemMedChem. 14:1349-1358. doi: 10.1002/cmdc.201900283

Pfalzgraff A, Correa W, Heinbockel L, Schromm AB, Lübow C, Gisch N, Martinez-de-Tejada G, Brandenburg K, Weindl G (2019) LPS-neutralizing peptides reduce outer membrane vesicle-induced inflammatory responses. Biochim Biophys Acta Mol Cell Biol Lipids. 1864:1503-1513. doi: 10.1016/j.bbalip.2019.05.018

Pfalzgraff A, Weindl G (2019) Intracellular lipopolysaccharide sensing as a potential therapeutic target for sepsis. Trends Pharmacol Sci 40:187-197. doi: 10.1016/j.tips.2019.01.001

Correa W, Heinbockel L, Martinez-de-Tejada G, Sanchez S, Garidel P, Schürholz T, Mier W, Dupont A, Hornef M, Gutsmann T, Mauss K, Weindl G, Brandenburg K (2019) Synthetic anti-lipopolysaccharide peptides (SALP) as effective inhibitors of pathogen-associated molecular patterns (PAMPs). Adv Exp Med Biol 1117:111-129. doi: 10.1007/978-981-13-3588-4_8

Klaschik K, Hauke J, Neidhardt G, Tränkle C, Surowy HM, Heilmann-Heimbach S, Rappl G, Mangold E, Arnold N, Niederacher D, Sutter C, Burwinkel B, Engel C, Wappenschmidt B, Meindl A, Ernst C, Weber-Lassalle K, Weber-Lassalle N, Schmidt S, Borde J, Schmutzler RK, Hahnen E, Pohl-Rescigno E (2019) The GPRC5A frameshift variant c.183del is not associated with increased breast cancer risk in BRCA1 mutation carriers. Int J Cancer 144:1761-1763. doi: 10.1002/ijc.32016

 


2014 - 2018 (Prof. Dr. Günther Weindl, PD Dr. Christian Tränkle)


Eine vollständige Liste der Publikationen von Herrn Prof. Dr. Günther Weindl und Herrn PD Dr. Christian Tränkle können Sie über PubMed abrufen.

 

Artikelaktionen